SCHEMBL2082271

SCHEMBL2082271

O=C(O)c1cn([C@@H]2C[C@@H]2F)c2c(Cl)c(Cl)ccc2c1=O

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.47
CSNK2A2 P19784 2/20 0.43
CSNK2B P67870 2/20 0.43
CSNK2A1 P68400 2/20 0.43
CHRM1 P11229 2/20 0.42
ALDH1A1 P00352 1/20 0.42
POLB P06746 1/20 0.42
CHRM2 P08172 1/20 0.42
OPRM1 P35372 1/20 0.42
OPRD1 P41143 1/20 0.42
KDM4E B2RXH2 3/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
CYP1A2 P05177 1/20 0.37
TOP2A P11388 4/20 0.37
TOP2B Q02880 4/20 0.37
DPP4 P27487 1/20 0.36
KCNH2 Q12809 2/20 0.34
CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2082268 1.00 CYP3A4 (0.47) CYP3A4CSNK2A2CSNK2BCSNK2A1CHRM1
SCHEMBL9147990 0.89 CYP3A4 (0.48) CYP3A4CHRM1ALDH1A1POLBCHRM2
SCHEMBL9147833 0.89 CYP3A4 (0.48) CYP3A4CHRM1ALDH1A1POLBCHRM2
SCHEMBL9147828 0.89 CYP3A4 (0.48) CYP3A4CHRM1ALDH1A1POLBCHRM2
SCHEMBL4747726 0.88 CYP3A4 (0.48) CYP3A4CSNK2A2CSNK2BCSNK2A1CHRM1
SCHEMBL2079699 0.83 TDP1 (0.44) CYP3A4ALDH1A1POLB
SCHEMBL2079698 0.83 TDP1 (0.44) CYP3A4ALDH1A1POLB
SCHEMBL23298393 0.81 CYP3A4 (0.56) CYP3A4CHRM1ALDH1A1POLBCHRM2
SCHEMBL9146693 0.81 CYP3A4 (0.48) CYP3A4CHRM1ALDH1A1POLBCHRM2
SCHEMBL9146697 0.81 CYP3A4 (0.48) CYP3A4CHRM1ALDH1A1POLBCHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902226-B2 Dehalogeno-compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 US disclosed
EP-1336611-B1 DEHALOGENO COMPOUNDS DAIICHI SEIYAKU CO (JP) 2007-09-05 EP disclosed
US-20070123560-A1 Dehalogeno-compounds DAIICHI PHARMACEUTICAL CO., LTD. 2007-05-31 US disclosed
US-20040063754-A1 Dehalogeno compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-01 US disclosed
EP-1336611-A1 DEHALOGENO COMPOUNDS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-08-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063754-A1 Dehalogeno compounds DEK, PGLS, RPS27L CYP3A4 198/4885CSNK2A2 2804/4885CSNK2B 2244/4885
US-20070123560-A1 Dehalogeno-compounds DEK, RPS27L, POLL CYP3A4 277/4885CSNK2A2 2387/4885CSNK2B 1608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.